

Antoine G Sreih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6158790/publications.pdf>

Version: 2024-02-01

51
papers

2,130
citations

279798

23
h-index

233421

45
g-index

53
all docs

53
docs citations

53
times ranked

2776
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	5.6	271
2	Vasculitis associated with immune checkpoint inhibitors—a systematic review. <i>Clinical Rheumatology</i> , 2018, 37, 2579-2584.	2.2	184
3	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
4	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
5	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130
6	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
7	Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3942-3951.	6.7	106
8	MIF and D-DT are potential disease severity modifiers in male MS subjects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8421-E8429.	7.1	83
9	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> , and <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1361-1368.	5.6	79
10	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
11	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
12	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
13	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.7	40
14	Characterisation of the nasal microbiota in granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1448-1453.	0.9	37
15	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
16	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2465-2469.	2.0	33
17	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1933-1937.	2.0	33
18	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33

#	ARTICLE	IF	CITATIONS
19	Development and validation of caseâ€finding algorithms for the identification of patients with antiâ€neutrophil cytoplasmic antibodyâ€associated vasculitis in large healthcare administrative databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1368-1374.	1.9	29
20	Patient involvement in medical research: what patients and physicians learn from each other. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 21.	2.7	29
21	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
22	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
23	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
24	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibodyâ€associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1529-1535.	2.0	25
25	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1198-1201.	2.0	24
26	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	4.3	24
27	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patientâ€, Physicianâ€, Imagingâ€, and Laboratoryâ€Based Assessments. <i>Arthritis Care and Research</i> , 2020, 72, 1296-1304.	3.4	23
28	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibodyâ€associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015, 42, 2204-2209.	2.0	22
29	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. <i>Journal of Rheumatology</i> , 2015, 42, 2448-2459.	2.0	21
30	Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3. <i>Clinical Rheumatology</i> , 2016, 35, 395-400.	2.2	21
31	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
32	Diagnostic delays in vasculitis and factors associated with time to diagnosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 184.	2.7	20
33	ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity. <i>Clinical Rheumatology</i> , 2015, 34, 943-948.	2.2	18
34	Optic Neuropathy Following Amiodarone Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 1108-1110.	1.2	16
35	Pembrolizumab-associated inflammatory myopathy. <i>Rheumatology</i> , 2018, 57, 397-398.	1.9	15
36	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 594-602.	4.4	14

#	ARTICLE	IF	CITATIONS
37	Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e17231.	4.3	13
38	Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1727-1733.	2.0	12
39	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 2077-2086.	5.6	12
40	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 40-44.	0.8	7
41	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
42	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
43	Health-related outcomes of importance to patients with Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 51-57.	0.8	6
44	Patient-reported outcomes in Takayasu's arteritis. <i>Presse Medicale</i> , 2017, 46, e225-e227.	1.9	4
45	Impact of vasculitis on employment and income. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 58-64.	0.8	4
46	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.8	3
47	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.8	3
48	Harnessing health plan enrollee data to boost membership in patient-powered research networks. <i>BMC Health Services Research</i> , 2020, 20, 462.	2.2	2
49	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	1.9	2
50	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
51	Prosthetic Valve Endocarditis Presenting as Loss of the Metallic Click Sound. <i>Southern Medical Journal</i> , 2004, 97, 1018-1019.	0.7	0